Mechanisms of tumor resistance to immune checkpoint blockade and combination strategies to overcome resistance

被引：57

作者：

Zhou, Xiaoting ^{[1
]}

Ni, Yanghong ^{[1
]}

Liang, Xiao ^{[1
]}

Lin, Yi ^{[1
]}

An, Biao ^{[1
]}

He, Xiang ^{[1
]}

Zhao, Xia ^{[1
]}

机构：

[1] Sichuan Univ, West China Hosp 2,Minist Educ, Dept Gynecol & Obstet,Key Lab Birth Defects & Rela, Dev & Related Dis Women & Children Key Lab Sichuan, Chengdu, Peoples R China

来源：

FRONTIERS IN IMMUNOLOGY | 2022年 / 13卷

基金：

中国国家自然科学基金;

关键词：

immune checkpoint blockade; combination therapy; T cell response; resistance mechanisms; immunotherapy; REGULATORY T-CELLS; CLASS-I ANTIGEN; PEMBROLIZUMAB PLUS CHEMOTHERAPY; ACQUIRED-RESISTANCE; PD-1; BLOCKADE; OPEN-LABEL; CANCER-IMMUNOTHERAPY; 1ST-LINE TREATMENT; IFN-GAMMA; DOWN-REGULATION;

D O I：

10.3389/fimmu.2022.915094

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Immune checkpoint blockade (ICB) has rapidly transformed the treatment paradigm for various cancer types. Multiple single or combinations of ICB treatments have been approved by the US Food and Drug Administration, providing more options for patients with advanced cancer. However, most patients could not benefit from these immunotherapies due to primary and acquired drug resistance. Thus, a better understanding of the mechanisms of ICB resistance is urgently needed to improve clinical outcomes. Here, we focused on the changes in the biological functions of CD8(+) T cells to elucidate the underlying resistance mechanisms of ICB therapies and summarized the advanced coping strategies to increase ICB efficacy. Combinational ICB approaches and individualized immunotherapies require further in-depth investigation to facilitate longer-lasting efficacy and a more excellent safety of ICB in a broader range of patients.

引用

页数：25

共 279 条

[1] Regulation of ROS in myeloid-derived suppressor cells through targeting fatty acid transport protein 2 enhanced anti-PD-L1 tumor immunotherapy [J].

Adeshakin, Adeleye Oluwatosin ;

Liu, Wan ;

Adeshakin, Funmilayo O. ;

Afolabi, Lukman O. ;

Zhang, Mengqi ;

Zhang, Guizhong ;

Wang, Lulu ;

Li, Zhihuan ;

Lin, Lilong ;

Cao, Qin ;

Yan, Dehong ;

Wan, Xiaochun .

CELLULAR IMMUNOLOGY, 2021, 362

[2] Overcoming Resistance to Tumor-Targeted and Immune-Targeted Therapies [J].

Aldea, Mihaela ;

Andre, Fabrice ;

Marabelle, Aurelien ;

Dogan, Semih ;

Barlesi, Fabrice ;

Soria, Jean-Charles .

CANCER DISCOVERY, 2021, 11 (04) :874-899

[3] Targeting Treg cells with GITR activation alleviates resistance to immunotherapy in murine glioblastomas [J].

Amoozgar, Zohreh ;

Kloepper, Jonas ;

Ren, Jun ;

Tay, Rong En ;

Kazer, Samuel W. ;

Kiner, Evgeny ;

Krishnan, Shanmugarajan ;

Posada, Jessica M. ;

Ghosh, Mitrajit ;

Mamessier, Emilie ;

Wong, Christina ;

Ferraro, Gino B. ;

Batista, Ana ;

Wang, Nancy ;

Badeaux, Mark ;

Roberge, Sylvie ;

Xu, Lei ;

Huang, Peigen ;

Shalek, Alex K. ;

Fukumura, Dai ;

Kim, Hye-Jung ;

Jain, Rakesh K. .

NATURE COMMUNICATIONS, 2021, 12 (01)

[4] Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer [J].

Anagnostou, Valsamo ;

Smith, Kellie N. ;

Forde, Patrick M. ;

Niknafs, Noushin ;

Bhattacharya, Rohit ;

White, James ;

Zhang, Theresa ;

Adleff, Vilmos ;

Phallen, Jillian ;

Wali, Neha ;

Hruban, Carolyn ;

Guthrie, Violeta B. ;

Rodgers, Kristen ;

Naidoo, Jarushka ;

Kang, Hyunseok ;

Sharfman, William ;

Georgiades, Christos ;

Verde, Franco ;

Illei, Peter ;

Li, Qing Kay ;

Gabrielson, Edward ;

Brock, Malcolm V. ;

Zahnow, Cynthia A. ;

Baylin, Stephen B. ;

Scharpf, Robert B. ;

Brahmer, Julie R. ;

Karchin, Rachel ;

Pardoll, Drew M. ;

Velculescu, Victor E. .

CANCER DISCOVERY, 2017, 7 (03) :264-276

[5] Pan-cancer analysis of the extent and consequences of intratumor heterogeneity [J].

Andor, Noemi ;

Graham, Trevor A. ;

Jansen, Marnix ;

Xia, Li C. ;

Aktipis, C. Athena ;

Petritsch, Claudia ;

Ji, Hanlee P. ;

Maley, Carlo C. .

NATURE MEDICINE, 2016, 22 (01) :105-+

[6] Oncolytic reovirus-mediated recruitment of early innate immune responses reverses immunotherapy resistance in prostate tumors [J].

Annels, Nicola E. ;

Simpson, Guy R. ;

Denyer, Mick ;

Arif, Mehreen ;

Coffey, Matt ;

Melcher, Alan ;

Harrington, Kevin ;

Vile, Richard ;

Pandha, Hardev .

MOLECULAR THERAPY-ONCOLYTICS, 2021, 20 :434-446

[7] Phase 1/2 Study of AUTO3 the First Bicistronic Chimeric Antigen Receptor (CAR) Targeting CD19 and CD22 Followed By an Anti-PD1 in Patients with Relapsed/Refractory (r/r) Diffuse Large B Cell Lymphoma (DLBCL): Results of Cohort 1 and 2 of the Alexander Study [J].

Ardeshna, Kirit M. ;

Marzolini, Maria A. V. ;

Norman, Jane ;

Al-Hajj, Muhammad ;

Thomas, Simon ;

Faulkner, Jim ;

Kotsopoulou, Ekaterini ;

Pule, Martin ;

Peddareddigari, Vijay G. R. ;

Khokhar, Nushmia Z. ;

Jonnaert, Maud ;

Chen, Robert ;

Osborne, Wendy .

BLOOD, 2019, 134

[8] Tumor-reprogrammed resident T cells resist radiation to control tumors [J].

Arina, Ainhoa ;

Beckett, Michael ;

Fernandez, Christian ;

Zheng, Wenxin ;

Pitroda, Sean ;

Chmura, Steven J. ;

Luke, Jason J. ;

Forde, Martin ;

Hou, Yuzhu ;

Burnette, Byron ;

Mauceril, Helena ;

Lowy, Israel ;

Sims, Tasha ;

Khodarev, Nikolai ;

Fu, Yang-Xin ;

Weichselbaum, Ralph R. .

NATURE COMMUNICATIONS, 2019, 10 (1)

[9] In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy [J].

Arlauckas, Sean P. ;

Garris, Christopher S. ;

Kohler, Rainer H. ;

Kitaoka, Maya ;

Cuccarese, Michael F. ;

Yang, Katherine S. ;

Miller, Miles A. ;

Carlson, Jonathan C. ;

Freeman, Gordon J. ;

Anthony, Robert M. ;

Weissleder, Ralph ;

Pittet, Mikael J. .

SCIENCE TRANSLATIONAL MEDICINE, 2017, 9 (389)

[10] Phenotype plasticity as enabler of melanoma progression and therapy resistance [J].

Arozarena, Imanol ;

Wellbrock, Claudia .

NATURE REVIEWS CANCER, 2019, 19 (07) :377-391

← 1 2 3 4 5 6 7 8 9 10 →